Inovio Pharmaceuticals, Inc. (INO) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you. Thank you. Thank you. Good afternoon, ladies and gentlemen, and welcome to the Inovio fourth quarter and full year 2025 financial results conference call. At this time, all lines are in a listen-only mode. Following the presentation, we will conduct a question and answer session. If at any time during this call you require immediate assistance, please press star zero for the operator. This call is being recorded on Thursday, March 12th, 2026. I would now like to turn the call over to Jenny Wilson. Please go ahead. Good afternoon, and thank you for joining the Inovio Fourth Quarter and Full Year 2025 Financial Results Conference Call. Joining me on today's call are Dr. Jackie Shea, President and Chief Executive Officer, Dr. Mike Sumner, Chief Medical Officer, Steve Ege, Chief Commercial Officer, and Peter Keyes, Chief Financial Officer. Today's call will review our corporate and financial information for the quarter and year ended December 31st, 2025, as well as provide a general business update. Following prepared remarks, we will conduct a question and answer segment. During the call, we will be making forward-looking statements regarding future events and the future performance of the company. These events relate to our business plans to develop Inovio's CNA medicines platform. which include clinical and regulatory developments and timing of clinical data readouts and planned regulatory submissions, our interactions with the FDA regarding our BLA for INO 3107, including our yet-to-be-scheduled meeting with the FDA to discuss eligibility for the Accelerated Approval Program, the potential benefits of INO 3107, along with capital resources, including the sufficiency of our cash resources, our expectations regarding competition, the size and growth of the p...